A fascinating episode and well worth your time! #ARTNetPodcast Episode 2: theartnetpodcast.riverside.com/e/resistance...

Resistance Before Treatment Begins: Why Some Tumors Are Already Primed to Survive

Why do some cancers fail treatment from the very beginning? In this episode of the ARTNet Podcast, Dr. David Goodrich speaks with Dr. Vlad C. Sandulache of Baylor College of Medicine about emerging re...

theartnetpodcast.riverside.com

Register now for the upcoming NCI Office of Data Sharing Seminar Series on July 29, 2026! Join Dr. Julian Hong of UCSF as he presents "Generalizable Multimodal AI Approaches to Advance Cancer Care Delivery." Register here: events.cancer.gov/ods/webinar/...

📢 Registration deadline extended! Join the 2026 #NCIDataJamboree (Nov. 16–18) using public cancer datasets to advance cancer research. Submit your project and register by July 27, 2026. events.cancer.gov/nci/datajamb...

At today's Functional Screens and Assays #ARTNetWG meeting, Dr. Erik Knudsen of @roswellpark.bsky.social presented an update on the collaborative drug screening project that Roswell Park is conducting with other ARTNet research centers.

📢 Registration is now open for the NCI Workshop on Understanding Plasticity and its Role Across the Cancer Continuum! 💻 Virtual participation is open to the public 🗓️ Sept. 23–24, 2026 🔗 Register here: events.cancer.gov/dcb/plastici...

📢 Registration is now open for the NCI Workshop on Understanding Plasticity and its Role Across the Cancer Continuum! 🗓️ September 23–24, 2026 💻 In-person speakers & virtual public participation Register here: events.cancer.gov/dcb/plastici...

Congratulations to Drs. Boyi Gan, XingXing Zang, Steven Hsesheng Lin, and all co-authors on this outstanding study published in Cell! www.sciencedirect.com/science/arti...

How do cancer-driving fusion proteins create their own vulnerabilities?A #ARTNetPublication in Cancer Research co-authored by Dr. Trever Bivona shows FET fusion oncoproteins impair ATM-mediated DNA damage repair, forcing tumors to rely on ATR signaling for survival. pubmed.ncbi.nlm.nih.gov/41811428/

FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy - PubMed

FET fusion oncoproteins subvert genome maintenance by impairing ATM activity, bridging two key fields-oncogene biology and DNA repair-and proposing ATR inhibition as a targeted therapeutic approach fo...

pubmed.ncbi.nlm.nih.gov

How do cancer-driving fusion proteins create their own vulnerabilities?A new #ARTNetPublication co-authored by Dr. Trever Bivona shows that FET fusion oncoproteins impair ATM-mediated DNA damage repair, forcing tumors to rely on ATR signaling for survival. pubmed.ncbi.nlm.nih.gov/41811428/

FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy - PubMed

FET fusion oncoproteins subvert genome maintenance by impairing ATM activity, bridging two key fields-oncogene biology and DNA repair-and proposing ATR inhibition as a targeted therapeutic approach fo...

pubmed.ncbi.nlm.nih.gov

At today’s Cell States, Metabolism & Inflammatory Microenvironment #ARTNetWGMeeting, Dr. Fatima Mechta-Grigoriou from Institut Curie presented her work on "Spatial determinants of stromal heterogeneity rriving resistance to immunotherapy in cancer".

🚀 Check this out — we’ve launched an AI for Cancer Webinar Catalog, updated weekly! nciartnet.org/en/resources... This curated catalog brings together AI in cancer research webinars from publicly available academic, industry, and professional organizations in one place.

At today’s #ARTNetSCMeeting, co-chair Dr. Alan Hutson of @roswellpark.bsky.social provided network updates, and Dr. Ping Mu of @yaleschoolofmed.bsky.social presented how his lab is leveraging AI tools to decode mechanisms of therapy resistance in prostate cancer.

🎙️ The inaugural episode of the #ARTNetPodcast is now live theartnetpodcast.riverside.com Join Dr. David Goodrich of @roswellpark.bsky.social & Dr. Jeff Tyner of @ohsuknight.bsky.social as they discuss cancer resistance, tumor evolution, & ARTNet’s mission to advance collaborative resistance research

🎙️ The inaugural episode of the #ARTNetPodcast is now live theartnetpodcast.riverside.com Join Dr. David Goodrich of @roswellpark.bsky.social & Dr. Jeff Tyner of @ohsuknight.bsky.social as they discuss cancer resistance, tumor evolution, & ARTNet’s mission to advance collaborative resistance research

The ARTNet Podcast

<p>Why do cancer treatments work for some patients at first, only to stop working later? In the premiere episode of the <a rel="noopener noreferrer nofollow" href="https://www.nciartnet.org?utm_source...

theartnetpodcast.riverside.com

At today’s Functional Screens and Assays #ARTNetWGMeeting, Dr. Anton Windfelder from the Fraunhofer Institute for Molecular Biology shared fascinating research on host-pathogen interactions using caterpillars as a model organism. The presentation sparked a highly engaging discussion .

New review just out: Drs. Erik S. Knudsen, Agnieszka K. Witkiewicz, and Sheheryar Kabraji of @roswellpark.bsky.social outline the evolving landscape of CDK inhibition: from the success of CDK4/6 inhibitors in breast cancer to next-gen strategies expanding into other tumor types. #CDK #BreastCancer

Nature Reviews Drug Discovery@natrevdrugdiscov.nature.com · 3mo ago

The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond www.nature.com/articles/s41... rdcu.be/ffR0W This new Review discusses how combination strategies, novel CDK2- and CDK4-selective inhibitors and biomarkers are addressing drug resistance and expanding therapeutic uses

New funding opportunity 🚨 National Cancer Institute (NCI) Division of Cancer Biology (DCB) has published FY26 Topics of Interest for Administrative Supplements. Check details here: www.cancer.gov/about-nci/or...

At today’s #ARTNetSCMeeting, Dr. Alan Hutson shared network updates and warmly welcomed new associate member Dr. Jennifer Wargo. Dr. Yu-Ting Chou presented on “Deciphering the interplay of β-catenin/YAP signaling and alveolar lineage plasticity during targeted therapy in #NSCLC.”

Venetoclax and Palbociclib in AML: Exploring New Findings reachmd.com/programs/on-...

Venetoclax and Palbociclib in AML: Exploring New Findings

Despite recent treatment advances, most patients with acute myeloid leukemia (AML)—especially those ineligible for intensive chemotherapy—ultimately relapse due to adaptive resistance to therapies lik...

reachmd.com

At today's Cell States, Metabolism & Inflammatory Microenvironment #ARTNetWGMeeting, Dr. Teresa Zimmers of Oregon Health & Science University presented on “Cancer Cachexia and Treatment Resistance,” sparking a lively and engaging discussion.

🚨 Registration Now Open! Join the Embedding Databases Workshop and help shape the future of AI-driven cancer research. 📅 Session A: April 8, 12:30–2:00 PM ET 📅 Session B: April 9, 2:00–3:30 PM ET apply.knowinnovation.com/ai-embedding... #AI #DataScience #HealthData

New #ARTNetPublication: A study by Dr. Trever Bivona and colleagues reveals that the pan-RAF inhibitor exarafenib shows strong activity against BRAF Class II/III NSCLC, a population with no approved targeted therapies and representing ~65% of BRAF-mutant cases. Read more: doi.org/10.1038/s414...

Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies - Nature Communications

While therapies targeting type I BRAF mutations have been developed, there are limited options for those with type II and III mutations. Here, the authors identify a subset of BRAF-mutant non-small ce...

doi.org

New #ARTNetPublication introduces MultiMap, a temporal photoproximity labeling approach to track dynamic EGFR interaction neighborhoods in real time. pubmed.ncbi.nlm.nih.gov/41254216/

Temporal photoproximity labeling of ligand-activated EGFR neighborhoods using MultiMap - PubMed

Photoproximity labeling proteomics (PLP) methods have recently shown that cell surface receptors can form lateral interactome networks. Here, we present a paired set of PLP workflows that dynamically track neighborhood changes for oncogenic epidermal growth factor receptor (EGFR) over time, both out …

pubmed.ncbi.nlm.nih.gov

At today’s #ARTNetSCMeeting, Dr. Alan Hutson provided network updates. Drs. Eric Knudsen and David Goodrich of @roswellpark.bsky.social presented the WG white paper proposal. Dr. Ann-Kathrin Eisfeld of OSU spoke on leveraging constitutional genetic diversity to increase knowledge about AML biology.

At today’s Functional Screens & Assay Development #ARTNetWGMeeting, Dr. Molly Ingersoll of @InstitutCochin presented “Mucosal Immunity and Challenges in Treating UTI,” triggering lively discussion.

At today's Cell States, Metabolism & Inflammatory Microenvironment WG Meeting, Dr. Dannielle Engle of Salk Institute for Biological Studies shared her work on glycan-driven rewiring of the pancreatic tumor microenvironment.

Congrats to all the authors! #ARTNetPublication

Soragni:Lab@alice.soragnilab.com · 6mo ago

Proud of this review on centering models and next gen techs to address and prevent acquired resistance in cancer. Cements the work that our working group within @nciartnet.org has done over the last couple years, glad it resonated with people

At today’s #ARTNetSCMeeting, Dr. Alan Hutson provided network updates. Drs. Shannon McWeeney and Daniel Bottomly highlighted a newly published study in Scientific Data, a collaborative effort across the ARTNet Consortium. Read the paper: www.nature.com/articles/s41...

#ARTNetPublication A new paper in Nature Comms by Dr. Trever Bivona shows that exarafenib, a pan-RAF inhibitor, has strong activity against BRAF Class II/III NSCLC, mutations that make up ~65% of BRAF-mutant cases and currently lack approved therapies. www.nature.com/articles/s41...

🧬 CIP-Net Project Spotlight UG3CA290454 is developing a preventive cancer vaccine for people with inherited BRCA1/2 mutations, using chimeric RNA-derived neoantigens to stop breast cancer before it forms. 👉Learn more on the CIP-Net website: www.nci-cipnet.org/en/members/u...